Fusion Medical preparing for clinical study of flowable gel to stop heavy surgical bleeding.
This article was originally published in The Gray Sheet
Executive Summary
FUSION MEDICAL'S FLOWABLE GEL COLLAGEN SEALANT CLINICAL TRIALS for cardiovascular and general surgery are slated to commence during the second quarter, Philip Sawyer, president and CEO of Fusion Medical Technologies said at a March 25 New York Society of Security Analysts meeting in New York City. The collagen-based sealant can stop active bleeding in approximately one minute, the company claims.
You may also be interested in...
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.
Could Eledon’s Anti-CD40L Change Transplant Medicine?
Eledon Pharmaceuticals’ CD40 Ligand blocker has yielded impressive results for post-transplant immunosuppression and cutting-edge transplant doctors have also used it for pig-to-human kidney and heart transplants, opening up the field of xenotransplantation.